• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清素 3A 受体中 RIC-3 伴侣蛋白的结合基序。

Binding motif for RIC-3 chaperon protein in serotonin type 3A receptors.

机构信息

Department of Cell Physiology and Molecular Biophysics and Center for Membrane Protein Research, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.

出版信息

J Gen Physiol. 2023 Jun 5;155(6). doi: 10.1085/jgp.202213305. Epub 2023 Apr 7.

DOI:10.1085/jgp.202213305
PMID:37026993
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10083716/
Abstract

Serotonin or 5-hydroxytryptamine type 3 (5-HT3) receptors belong to the family of pentameric ligand-gated ion channels (pLGICs) that are therapeutic targets for psychiatric disorders and neurological diseases. Due to structural conservation and significant sequence similarities of pLGICs' extracellular and transmembrane domains, clinical trials for drug candidates targeting these two domains have been hampered by off-subunit modulation. With the present study, we explore the interaction interface of the 5-HT3A subunit intracellular domain (ICD) with the resistance to inhibitors of choline esterase (RIC-3) protein. Previously, we have shown that RIC-3 interacts with the L1-MX segment of the ICD fused to maltose-binding protein. In the present study, synthetic L1-MX-based peptides and Ala-scanning identify positions W347, R349, and L353 as critical for binding to RIC-3. Complementary studies using full-length 5-HT3A subunits confirm that the identified Ala substitutions reduce the RIC-3-mediated modulation of functional surface expression. Additionally, we find and characterize a duplication of the binding motif, DWLR…VLDR, present in both the MX-helix and the transition between the ICD MA-helix and transmembrane segment M4. Analogous Ala substitutions at W447, R449, and L454 disrupt MAM4-peptide RIC-3 interactions and reduce modulation of functional surface expression. In summary, we identify the binding motif for RIC-3 in 5-HT3A subunits at two locations in the ICD, one in the MX-helix and one at the MAM4-helix transition.

摘要

血清素或 5-羟色胺 3 型(5-HT3)受体属于五聚体配体门控离子通道(pLGIC)家族,是精神障碍和神经疾病的治疗靶点。由于 pLGIC 的细胞外和跨膜结构域具有结构保守性和显著的序列相似性,针对这些两个结构域的药物候选物的临床试验受到亚基外调制的阻碍。在本研究中,我们探索了 5-HT3A 亚基细胞内结构域(ICD)与胆碱酯酶抑制剂抗性(RIC-3)蛋白相互作用的界面。先前,我们已经表明 RIC-3 与融合到麦芽糖结合蛋白的 ICD 的 L1-MX 片段相互作用。在本研究中,基于合成 L1-MX 的肽和丙氨酸扫描确定了位置 W347、R349 和 L353 对于与 RIC-3 结合是关键的。使用全长 5-HT3A 亚基的互补研究证实,鉴定的丙氨酸取代减少了 RIC-3 介导的功能性表面表达的调制。此外,我们发现并表征了结合基序的重复,即 DWLR…VLDR,存在于 MX 螺旋和 ICD MA 螺旋与跨膜片段 M4 之间的过渡区。在 W447、R449 和 L454 处的类似 Ala 取代破坏了 MAM4-肽 RIC-3 相互作用并减少了功能性表面表达的调制。总之,我们在 5-HT3A 亚基的 ICD 中两个位置确定了 RIC-3 的结合基序,一个在 MX 螺旋,一个在 MAM4-螺旋过渡区。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/10083716/fa5152d0bbf1/JGP_202213305_Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/10083716/49b55ae725da/JGP_202213305_Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/10083716/bde6929bc6ef/JGP_202213305_Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/10083716/9cf46bc46d0e/JGP_202213305_Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/10083716/f46ca9decbf2/JGP_202213305_Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/10083716/0c917da732b4/JGP_202213305_Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/10083716/fa5152d0bbf1/JGP_202213305_Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/10083716/49b55ae725da/JGP_202213305_Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/10083716/bde6929bc6ef/JGP_202213305_Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/10083716/9cf46bc46d0e/JGP_202213305_Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/10083716/f46ca9decbf2/JGP_202213305_Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/10083716/0c917da732b4/JGP_202213305_Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/10083716/fa5152d0bbf1/JGP_202213305_Fig6.jpg

相似文献

1
Binding motif for RIC-3 chaperon protein in serotonin type 3A receptors.血清素 3A 受体中 RIC-3 伴侣蛋白的结合基序。
J Gen Physiol. 2023 Jun 5;155(6). doi: 10.1085/jgp.202213305. Epub 2023 Apr 7.
2
Direct interaction of the resistance to inhibitors of cholinesterase type 3 protein with the serotonin receptor type 3A intracellular domain.3型胆碱酯酶抑制剂抗性蛋白与3A型5-羟色胺受体细胞内区域的直接相互作用。
J Neurochem. 2016 May;137(4):528-38. doi: 10.1111/jnc.13578. Epub 2016 Mar 11.
3
Delineating the Site of Interaction of the 5-HT Receptor with the Chaperone Protein RIC-3.确定5-羟色胺受体与伴侣蛋白RIC-3的相互作用位点。
Biophys J. 2020 Feb 25;118(4):934-943. doi: 10.1016/j.bpj.2019.11.3380. Epub 2019 Nov 28.
4
Pentameric quaternary structure of the intracellular domain of serotonin type 3A receptors.5-羟色胺3A受体细胞内结构域的五聚体四级结构。
Sci Rep. 2016 Apr 5;6:23921. doi: 10.1038/srep23921.
5
RIC-3 exclusively enhances the surface expression of human homomeric 5-hydroxytryptamine type 3A (5-HT3A) receptors despite direct interactions with 5-HT3A, -C, -D, and -E subunits.RIC-3 专门增强人源同型 5-羟色胺 3A(5-HT3A)受体的表面表达,尽管与 5-HT3A、-C、-D 和 -E 亚基直接相互作用。
J Biol Chem. 2010 Aug 27;285(35):26956-26965. doi: 10.1074/jbc.M110.122838. Epub 2010 Jun 3.
6
Triple arginines as molecular determinants for pentameric assembly of the intracellular domain of 5-HT receptors.三精氨酸作为 5-HT 受体细胞内结构域五聚体组装的分子决定因素。
J Gen Physiol. 2019 Sep 2;151(9):1135-1145. doi: 10.1085/jgp.201912421. Epub 2019 Aug 13.
7
5-HT Receptor MX Helix Contributes to Receptor Function.5-HT 受体 MX 螺旋有助于受体功能。
ACS Chem Neurosci. 2022 Aug 3;13(15):2338-2345. doi: 10.1021/acschemneuro.2c00339. Epub 2022 Jul 22.
8
Cryo-EM reveals two distinct serotonin-bound conformations of full-length 5-HT receptor.低温电镜揭示全长 5-HT 受体与血清素结合的两种不同构象。
Nature. 2018 Nov;563(7730):270-274. doi: 10.1038/s41586-018-0660-7. Epub 2018 Oct 31.
9
Mutagenic analysis of the intracellular portals of the human 5-HT3A receptor.人类 5-HT3A 受体胞内通道的诱变分析。
J Biol Chem. 2013 Nov 1;288(44):31592-601. doi: 10.1074/jbc.M113.503300. Epub 2013 Sep 12.
10
The minimum M3-M4 loop length of neurotransmitter-activated pentameric receptors is critical for the structural integrity of cytoplasmic portals.神经递质激活的五聚体受体的最小 M3-M4 环长度对于细胞质门的结构完整性至关重要。
J Biol Chem. 2013 Jul 26;288(30):21558-68. doi: 10.1074/jbc.M113.481689. Epub 2013 Jun 5.

本文引用的文献

1
Structures of highly flexible intracellular domain of human α7 nicotinic acetylcholine receptor.人α7烟碱型乙酰胆碱受体内高度灵活的细胞内结构域的结构
Nat Commun. 2022 Feb 10;13(1):793. doi: 10.1038/s41467-022-28400-x.
2
Therapeutic Targeting of 7 Nicotinic Acetylcholine Receptors.治疗性靶向 7 型烟碱型乙酰胆碱受体
Pharmacol Rev. 2021 Jul;73(3):1118-1149. doi: 10.1124/pharmrev.120.000097.
3
Structure and gating mechanism of the α7 nicotinic acetylcholine receptor.α7 型烟碱型乙酰胆碱受体的结构与门控机制。
Cell. 2021 Apr 15;184(8):2121-2134.e13. doi: 10.1016/j.cell.2021.02.049. Epub 2021 Mar 17.
4
Structure, Function and Physiology of 5-Hydroxytryptamine Receptors Subtype 3.5-羟色胺受体亚型 3 的结构、功能和生理学。
Subcell Biochem. 2021;96:373-408. doi: 10.1007/978-3-030-58971-4_11.
5
High-resolution structures of multiple 5-HTR-setron complexes reveal a novel mechanism of competitive inhibition.多个5-羟色胺受体-血清素复合物的高分辨率结构揭示了一种竞争性抑制的新机制。
Elife. 2020 Oct 16;9:e57870. doi: 10.7554/eLife.57870.
6
Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials.近年来,蛋白质-蛋白质相互作用调节剂的研发取得了进展:作用机制和临床试验。
Signal Transduct Target Ther. 2020 Sep 23;5(1):213. doi: 10.1038/s41392-020-00315-3.
7
NACHO Engages N-Glycosylation ER Chaperone Pathways for α7 Nicotinic Receptor Assembly.NACHO参与α7烟碱型受体组装的N-糖基化内质网伴侣途径。
Cell Rep. 2020 Aug 11;32(6):108025. doi: 10.1016/j.celrep.2020.108025.
8
Delineating the Site of Interaction of the 5-HT Receptor with the Chaperone Protein RIC-3.确定5-羟色胺受体与伴侣蛋白RIC-3的相互作用位点。
Biophys J. 2020 Feb 25;118(4):934-943. doi: 10.1016/j.bpj.2019.11.3380. Epub 2019 Nov 28.
9
Agonist Selectivity and Ion Permeation in the α3β4 Ganglionic Nicotinic Receptor.α3β4 型烟碱型乙酰胆碱受体激动剂选择性和离子通透性。
Neuron. 2019 Nov 6;104(3):501-511.e6. doi: 10.1016/j.neuron.2019.07.030. Epub 2019 Sep 2.
10
Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A Systematic Review and Meta-Analysis of Clinical Trials.Bcl-2抑制剂维奈托克在血液系统恶性肿瘤中的疗效与安全性:一项临床试验的系统评价和荟萃分析
Front Pharmacol. 2019 Jun 21;10:697. doi: 10.3389/fphar.2019.00697. eCollection 2019.